PROM1 and neoplasm: In addition, flow cytometric analysis of tumor cells harvested from the control and fatostatin mice indicated that fatostatin-treated tumor cells contained a lower percentage of CD133+ cells (Figure 5D) and higher miR-142-5p level (Figure 5E).